Walaa A Rajkhan

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Disease relapse post remission is a major predictor of poor outcome for patients with AML. The relapse rates range from 40% for patients with favorable cytogenetic abnormalities at diagnosis to 90% for patients with adverse cytogenetics. Patients who relapse respond heterogeneously to salvage treatment. Long-term disease control may be achieved by allogenic(More)
  • 1